Gynecologic Oncology Group clinical trials
Listed in the registry as: Research network.
The registry lists 188 studies whose lead sponsor is Gynecologic Oncology Group. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 9, 2026.
Keep track of what changes. Save the Gynecologic Oncology Group studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions Gynecologic Oncology Group leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Carcinoma54Ovarian Neoplasms38Uterine Cervical Neoplasms38Carcinoma, Ovarian Epithelial36Cystadenocarcinoma, Serous26Fallopian Tube Neoplasms26Endometrial Neoplasms24Carcinoma, Adenosquamous16Adenocarcinoma, Clear Cell14Sarcoma14Carcinoma, Endometrioid13Vulvar Neoplasms11Brenner Tumor10Peritoneal Neoplasms10
Studies
Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 →
- Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial CancerRecruitingNCT01000259
- Abemaciclib and Letrozole to Treat Endometrial CancerActive, not recruitingNCT04393285Phase 2
- Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 2
- Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199WithdrawnNCT01445275
- Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial CancerCompletedNCT01164735
- Biomarkers in Samples From Patients With Endometrial CancerWithdrawnNCT01199250
- Biomarkers in Blood and Tissue Samples From Patients With Uterine CancerCompletedNCT01344837
- Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial CancerCompletedNCT01198171
- Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the VulvaStatus unknownNCT01595061Phase 2
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT01720173Phase 2
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial CancerStatus unknownNCT00942357Phase 3
- Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node DissectionStatus unknownNCT01500512
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial CancerStatus unknownNCT02065687Phase 2/3
- Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerStatus unknownNCT01366183
- Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial CancerTerminatedNCT00577317Phase 3
- Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and LymphadenectomyCompletedNCT01406769Phase 2
- Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial HyperplasiaTerminatedNCT00503581Phase 2
- Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01266460Phase 2
- Incidence of Cancer in Women at Increased Genetic Risk of Ovarian CancerCompletedNCT01139957
- Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by SurgeryTerminatedNCT01533207Phase 3
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both OvariesCompletedNCT00305695Phase 2
- Paclitaxel in Treating Patients With Ovarian Stromal CancerCompletedNCT00006227Phase 2
- Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete RemissionWithdrawnNCT00693342Phase 3
- Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian CancerCompletedNCT00445887Phase 2
- Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian CancerCompletedNCT00003644Phase 3
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00011986Phase 3
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerStatus unknownNCT00807768Phase 3
- Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00407758Phase 2
- Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial CancerStatus unknownNCT00006903Phase 2
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01267253Phase 2
- Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical CancerStatus unknownNCT01295502Phase 1
- EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01489371Phase 1
- Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerStatus unknownNCT00958698Not applicable
- Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal CancerStatus unknownNCT01372787
- A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00939809Phase 2
- Topotecan in Treating Women With Persistent or Recurrent Cervical CancerCompletedNCT00087126Phase 2
- Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00114218Phase 2
- ABI-007 in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT00309959Phase 2
- Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the CervixCompletedNCT00064077Phase 3
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine CancerCompletedNCT00112489Phase 2
- Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00114166Phase 2
- Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube CancerCompletedNCT00569673Phase 2
- Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00459290Phase 2
- Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01295489
- Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicable
- YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving ChemotherapyTerminatedNCT00899093
- Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic NeoplasiaCompletedNCT00003702Phase 3
- Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal CancerTerminatedNCT00005029Phase 2
- Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical CancerCompletedNCT01098630
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyCompletedNCT01080521